Updated time: 2024-10-24 10:17:05
We reported previously the discovery of a novel broad-spectrum antimicrobial peptide HBcARD. Using this HBcARD peptide as a template, we designed a new antimicrobial peptide derivative by the truncations and D-arginine substitution. This new peptide can be synthesized at a lower cost, and is more resistant to proteolytic degradation, and exhibits an improved protection efficacy in vivo. It has the potential to be a novel antibiotic for clinical medicine.
Antibiotic-resistant bacteria is a major threat to our health worldwide. Our patented HBcARD peptide can kill both Gram-negative and Gram-positive bacteria, including antibiotics-resistant clinical isolates.
12A-1030801
TW I635095, 、ZA 2018/07763、JP 7161263、US 12,084,479 B2
Novel antibiotics
Chiaho Shih, Heng-Li Chen, Pei-Yi Su
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Antimicrobial peptides derived from Hepatitis B virus core protein arginine-rich dormain